Portal de investigación
- Inicio
- Proyectos y Estudios
- ENSAYO FASE III, RANDOMIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, MULTICÉNTRICO, INTERNACIONAL CON OSIMERTINIB COMO TRATAMIENTO DE MANTENIMIENTO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO (ESTADIO III) LOCALMENTE AVANZADO E IRRESECABLE, CON MUTACIÓN DE EGFR POSITIVA, CUYA ENFERMEDAD NO HA PROGRESADO DESPUÉS DE TRATAMIENTO DEFINITIVO CON QUIMIORADIOTERAPIA BASADA EN PLATINO (LAURA).
ENSAYO FASE III, RANDOMIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, MULTICÉNTRICO, INTERNACIONAL CON OSIMERTINIB COMO TRATAMIENTO DE MANTENIMIENTO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO (ESTADIO III) LOCALMENTE AVANZADO E IRRESECABLE, CON MUTACIÓN DE EGFR POSITIVA, CUYA ENFERMEDAD NO HA PROGRESADO DESPUÉS DE TRATAMIENTO DEFINITIVO CON QUIMIORADIOTERAPIA BASADA EN PLATINO (LAURA).
Datos básicos
- Código:
- D5160C00048
- Protocolo:
- D5160C00048
- EUDRACT:
- 2018-001061-16
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2018
- Año de finalización:
- 2025
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.
Cordoba, Raul; (...); Martin Garcia-Sancho, Alejandro
Article. 10.1080/17474086.2024.2313457. 2024
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
Martínez-Banaclocha N; (...); Gumà J
Article. 10.3390/cancers16051034. 2024
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.
Casado, MA; (...); Grp MULTIDEX-EMD
Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results
Ponce Aix, S.; (...); Paz-Ares, L.
Meeting Abstract. 2021
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Camidge DR; (...); Smit E
Article. 10.1016/j.cllc.2022.03.003. 2022
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)
Morgensztern, D; (...); ABOUND 2L Investigators
Article. 10.1002/cncr.31779. 2018
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
Romero, A; (...); Provencio, M
Meeting Abstract. 10.1016/j.jtho.2019.08.1463. 2019
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro, A; (...); Cho, B C
Article. 10.1016/j.annonc.2023.10.117. 2024
An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.
Dowlati, Afshin; (...); Carpeno, Javier de Castro
Meeting Abstract. 2022
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Antimicrobial stewardship programme implementation in a medical ward
Ruiz, J; (...); Poveda, JL
Article. 2018
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.
Ruano-Ravina A; (...); Oramas J
Article. 10.21037/tlcr-21-559. 2021
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study
Conde, E; (...); Lopez-Rios, F
Article. 10.1016/j.jtho.2019.07.005. 2019
Assessment of Gender Differences in the Psychosocial and Economic Impact on Patients with Stage IV Non-Small Cell Lung Cancer
Garrido, P; (...); Vinolas, N
Meeting Abstract. 10.1016/j.jtho.2019.08.685. 2019
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection The Phase 2 DURVAST Study
Gonzalez-Cao, M; (...); Rosell, R
Article. 10.1001/jamaoncol.2020.0465. 2020
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.
Vicente-Baz D; (...); Provencio M
Article. 10.1016/j.patol.2019.11.002. 2020
ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
Nadal, E; (...); Bruna, J
Meeting Abstract. 10.1016/j.jtho.2019.08.826. 2019
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.
Andric, Zoran; (...); Ciardiello, Fortunato
Article. 10.1016/j.jtocrr.2022.100461. 2023
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Garcia-Sanchez, J.; (...); Lahoz, A.
Meeting Abstract. 2021
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
SAnchez, JosE GarcIa; (...); Lahoz, Agustin
Meeting Abstract. 2020
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Vidal, O. J. Juan; (...); Wolf, J.
Meeting Abstract. 10.1016/j.annonc.2023.09.2424. 2023
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L; (...); de la Cruz-Merino L
Article. 10.3389/fimmu.2024.1293931. 2024
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
Jimenez-Cortegana, C; (...); de la Cruz-Merino, L
Article. 10.1136/jitc-2020-002323. 2021
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Moran, T; (...); Torres, JMS
Article. 10.1016/j.cllc.2020.04.011. 2020
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
Rodriguez-Pinilla SM; (...); Cordoba, Raul
Article. 10.1111/bjh.16741. 2021
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)
Franco, FF; (...); Provencio, M
Meeting Abstract. 10.1016/j.annonc.2021.08.1771. 2021
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
Zugazagoitia, J; (...); Garrido, P
Article. 10.1016/j.lungcan.2019.05.032. 2019
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Zugazagoitia, J; (...); Paz-Ares, L
Article. 10.1093/annonc/mdy512. 2019
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Comprehensive cross-platform comparison of methodologies for noninvasive EGFR mutation testing: Results of the RING observational trial.
Romero, Atocha; (...); Provencio-Pulla, Mariano
Meeting Abstract. 2020
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: Results of the RING observational trial.
Romero A; (...); Provencio M
Article. 10.1002/1878-0261.12832. 2020
Comprehensive genomic profile by Foundation Medicine test in guiding routine decisions for secondline treatment in advanced non-small cell breast cancer (NSCLC): Preliminary results of lung-ONE study.
Rojo, Federico; (...); De Castro, Javier
Meeting Abstract. 2020
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years
Provencio, M; (...); Rueda, A
Letter. 10.1080/10428194.2018.1509322. 2019
Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
García-Campelo R; (...); Dómine M
Correction. 10.1007/s12094-023-03290-7. 2023
Correction: Pardo-Sánchez et al. Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers 2021, 13 , 2980.
Pardo-Sanchez, Jose Miguel; (...); Farràs R
Article. 10.3390/cancers13194825. 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].
Reck, M.; (...); John, T.
Correction. 10.1016/j.esmoop.2021.100345. 2021
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN
Trillo, JL; (...); Torres, C
Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Current treatment landscape for oligometastatic non-small cell lung cancer
Garde-Noguera, Javier; (...); Counago, Felipe
Article. 10.5306/wjco.v13.i6.485. 2022
CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.
Becker JH; (...); Shimamura T
Article. 10.1158/0008-5472.CAN-19-0024. 2019
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Aransay, N. Reguart; (...); Vila, A. Lloansi
Meeting Abstract. 10.1016/j.annonc.2023.09.2442. 2023
Chemokine Receptor CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Becker, J; (...); Shimamura, T
Meeting Abstract. 10.1016/j.jtho.2019.08.1478. 2019
Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Suay, G.; (...); Juan-Vidal, O.
Meeting Abstract. 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn, Myung-Ju; (...); Sands, Jacob
Article. 10.1200/JCO-24-01544. 2024
Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01
Sands, J.; (...); Ahn, M-J
Meeting Abstract. 2024
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study)
Franco, F; (...); Pulla, MP
Meeting Abstract. 10.1016/j.annonc.2020.08.1694. 2020
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Determination of essential biomarkers in lung cancer: A real-world data study in Spain
Calvo de Juan, V.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2022.02.048. 2022
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
Provencio, Mariano; (...); Torrente, Maria
Article. 10.1186/s12885-022-09830-8. 2022
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Development of a predictive model for early detection of lung cancer: SREAL-eLUNG study
Vidal, O. J. Juan; (...); Martinez, B. Valdivieso
Meeting Abstract. 2023
Development of severity and mortality prediction models for covid-19 patients at emergency department including the chest x-ray.
Calvillo-Batllés P; (...); Martí-Bonmatí L
Article. 10.1016/j.rxeng.2021.09.004. 2022
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J; (...); Palanca S
Article. 10.3390/cancers11081196. 2019
Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study
Reinmuth, Niels; (...); Bondarenko, Igor
Meeting Abstract. 2022
ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN
Fernandez-Barcelo, C.; (...); Sampietro-Colom, L.
Meeting Abstract. 2023
ECONOMIC IMPACT OF THE NSCLC MOLECULAR DIAGNOSIS IN SPAIN: A RETROSPECTIVE ANALYSIS OF HEALTHCARE RESOURCES USE AND ASSOCIATED COSTS FROM THE LUNG-ONE STUDY
de Castro, J; (...); Rojo, F
Meeting Abstract. 2020
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)
Angelats, L; (...); Costa, EC
Meeting Abstract. 2019
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
Brandao, Mariana da Rocha Almeida; (...); Felip, Enriqueta
Meeting Abstract. 2024
Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
Reck, M; (...); Spigel, DR
Meeting Abstract. 2018
Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
Morgensztern, D; (...); Ong, TJ
Meeting Abstract. 10.1016/j.jtho.2018.08.626. 2018
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma
Pulido, I; (...); Shimamura, T
Article. 10.1158/0008-5472.CAN-20-0141. 2020
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
Franco, F; (...); Provencio, M
Article. 10.1371/journal.pone.0251761. 2021
European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.
Suay, Guillermo, Aparisi, Francisco, Juan-Vidal, Oscar
Article. 10.21037/cco-23-100. 2024
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
Conde, E; (...); Lopez-Rios, F
Meeting Abstract. 10.1016/j.jtho.2018.08.785. 2018
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.
Arriola E; (...); Felip E
Article. 10.1007/s40261-024-01379-7. 2024
Exploratory analysis for the implementation of antineoplastic logarithmic dose banding
Albert-Mari, A; (...); Poveda-Andres, JL
Article. 10.1007/s11096-018-0714-9. 2018
Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group
Cao, MG; (...); Costa, RR
Meeting Abstract. 10.1016/j.annonc.2020.08.1589. 2020
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)
Calvo, V; (...); Pulla, MP
Meeting Abstract. 10.1016/j.annonc.2020.08.1555. 2020
FAMetA: a mass isotopologue-based tool for the comprehensive analysis of fatty acid metabolism.
Alcoriza-Balaguer MI; (...); Lahoz A
Article. 10.1093/bib/bbad064. 2023
Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)
Calvo, V.; (...); Provencio, M.
Meeting Abstract. 2021
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02
Pulla, MP; (...); Casado, MDI
Meeting Abstract. 2018
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)
Carbone, David Paul; (...); Reck, Martin
Meeting Abstract. 2023
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
Carbone, David Paul; (...); Reck, Martin
Meeting Abstract. 10.1200/JCO.2023.41.17_suppl.LBA9023. 2023
First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
Andric, Z. G.; (...); Ciardiello, F.
Meeting Abstract. 2021
First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update
Baclin, Firas; (...); Reck, Martin
Meeting Abstract. 2024
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Reck, Martin; (...); John, Tom
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9000. 2021
First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
Paz-Ares, L.; (...); Carbone, D. P.
Meeting Abstract. 2021
First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA
Reinmuth, N.; (...); John, T.
Meeting Abstract. 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares, Luis; (...); Reck, Martin
Article. 10.1016/S1470-2045(20)30641-0. 2021
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready, Neal E.; (...); Paz-Ares, Luis
Article. 10.1136/jitc-2022-006127. 2023
First-line Nivolumab plus Ipilimumab plus Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
Carbone, D.; (...); Lu, S.
Meeting Abstract. 2021
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Paz-Ares, Luis G.; (...); Carbone, David P.
Article. 10.1016/j.jtho.2022.10.014. 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M; (...); John T
Article. 10.1016/j.esmoop.2021.100273. 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck, Martin; (...); Carbone, David P.
Article. 10.1016/j.ejca.2023.01.015. 2023
Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
Reck, Martin; (...); Paz-Ares, Luis G.
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.8560. 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
Reck M; (...); Paz-Ares LG
Article. 10.1016/j.ejca.2024.114296. 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; (...); Reck M
Article. 10.1136/jitc-2023-008189. 2024
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)
Le, Xiuning; (...); Wang, Jie
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS8666. 2024
FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
Le, X.; (...); Wang, J.
Meeting Abstract. 2024
GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC)-A randomized, double-blind trial.
Ghiringhelli, Francois; (...); Basse, Linda
Meeting Abstract. 2022
GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Aparisi Aparisi, F. D. A.; (...); Ghiringhelli, F.
Meeting Abstract. 10.1016/j.annonc.2023.09.2491. 2023
Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas
Pros, E; (...); Sanchez-Cespedes, M
Meeting Abstract. 10.1016/j.jtho.2019.08.878. 2019
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E; (...); Sanchez-Cespedes M
Article. 10.1016/j.annonc.2019.09.001. 2020
Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study
Lopez Castro, R.; (...); Ponce Aix, S.
Meeting Abstract. 2023
Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience.
Girones, R; (...); Juan-Vidal, O
Article. 10.1111/ecc.12950. 2018
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
Felip, E.; (...); Duruisseaux, M.
Meeting Abstract. https://doi.org/10.1016/j.jtho.2024.09.056. 2024
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
Muñoz-Unceta N; (...); Grupo de trombosis y cáncer SEOM
Article. 10.1016/j.ejca.2020.10.002. 2020
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations
Suay, Guillermo; (...); Lahoz, Agustin
Review. 10.1016/j.canlet.2024.217317. 2024
Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients
Escoin-Perez C, Blasco S, Juan-Vidal O
Review. 10.1016/j.lungcan.2020.03.026. 2020
Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy
Melian Sosa, M.; (...); Lorente, D.
Meeting Abstract. 2018
Immunogenicity of COVID-19 vaccines in lung cancer patients.
Provencio M; (...); Calvo V
Article. 10.1016/j.lungcan.2023.107323. 2023
Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial
Guckenberger, M; (...); Stahel, RA
Meeting Abstract. 10.1016/j.annonc.2020.08.1731. 2020
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/cancers15061705. 2023
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection.
García-Ortega A; (...); Martínez-García MÁ
Article. 10.1016/j.jinf.2021.01.003. 2021
Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation
Pardo-Sanchez, JM; (...); Farras, R
Article. 10.3390/cancers13122980. 2021
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer
Rodriguez, LPA; (...); Bunn, P
Meeting Abstract. 2019
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Mok, Tony S. K.; (...); Barlesi, Fabrice
Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8509. 2024
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.
Palaz N-Carri N, Natalia; (...); de la Cruz-Merino, Luis
Article. 10.1158/1078-0432.CCR-22-0588. 2022
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.
Merino, LD; (...); Dominguez, AR
Meeting Abstract. 2020
LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics
Alcoriza-Balaguer, MI; (...); Lahoz, A
Article. 10.1021/acs.analchem.8b03409. 2019
Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity
Spigel, DR; (...); Bunn, P
Meeting Abstract. 2021
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E; (...); de Sevilla AF
Article. 10.1007/s00277-020-04056-9. 2020
Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
Melian, M; (...); Juan, O
Article. 10.1111/1759-7714.12873. 2018
Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).
Calvo, V; (...); Provencio, M
Meeting Abstract. 2021
Lung cancer symptoms at diagnosis: results of a nationwide registry study.
Ruano-Raviña A; (...); Cerezo S
Article. 10.1136/esmoopen-2020-001021. 2020
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Garrido, P; (...); Felip, E
Article. 10.1002/cam4.4135. 2021
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Lopez, PG; (...); Calvo, JP
Meeting Abstract. 2018
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Remon, J; (...); Reguart, N
Article. 10.1016/j.lungcan.2020.06.034. 2020
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)
Angelats, L; (...); Carcereny, E
Meeting Abstract. 10.1016/j.jtho.2019.08.808. 2019
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
MS201944-0170: A phase Ila study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.
Ciardiello, Fortunato; (...); Galffy, Gabriella
Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.TPS9123. 2019
Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
Franco, F; (...); Provencio, M
Article. 10.3390/curroncol28020118. 2021
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
Ponce, S; (...); Nadal, E
Review. 10.1016/j.critrevonc.2019.03.017. 2019
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Morgensztern D; (...); Ong TJ
Article. 10.3389/fonc.2020.569715. 2021
Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study
Spigel, D; (...); Thomas, M
Meeting Abstract. 10.1016/j.jtho.2019.08.604. 2019
nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study
Spigel, DR; (...); Thomas, M
Meeting Abstract. 2018
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; (...); ABOUND.sqm Investigators
Article. 10.1016/j.cllc.2020.09.007. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
NIVEX TRIAL (GECP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients
Rodriguez-Abreu, D; (...); Majem, M
Meeting Abstract. 10.1016/j.jtho.2018.08.1467. 2018
NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Nadal, E.; (...); Bruna, J.
Meeting Abstract. 2022
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2020
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2020
Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2021
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
Reinmuth, Niels; (...); Bondarenko, Igor
Article. 10.1158/1078-0432.CCR-24-0013. 2024
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.
Mesía R; (...); Pujol E
Article. 10.1007/s11864-019-0686-6. 2019
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Isla D; (...); Provencio M
Article. 10.1016/j.lungcan.2018.11.041. 2019
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M; (...); Calvo V
Article. 10.1186/s12885-021-07922-5. 2021
OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX
Terrasa, J; (...); Provencio, M
Meeting Abstract. 2021
Pain Standards for Accredited Healthcare Organizations (ACDON Project): A Mixed Methods Study.
Perez, Concepcion; (...); Mira, Jose J.
Article. 10.3390/jpm11020102. 2021
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
Remon J; (...); Besse B
Article. 10.1016/j.cllc.2021.07.008. 2021
Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I
Ponce Aix, S.; (...); Paz-Ares, L.
Meeting Abstract. 10.1016/j.annonc.2021.10.179. 2021
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martin Garcia-Sancho, Alejandro; (...); Cordoba, Raul
Article. 10.1111/bjh.18941. 2023
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.
Gonzalez-Cao, M; (...); Rosell, R
Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.2501. 2019
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E; (...); Bruna J
Article. 10.1200/JCO.22.02561. 2023
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn, Myung-Ju; (...); Paz-Ares, Luis
Article. 10.1080/14796694.2024.2402152. 2024
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
Garde-Noguera, J; (...); Juan-Vidal, O
Article. 10.1007/s12094-017-1829-5. 2018
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients (vol 20, pg 1072, 2018)
Garde-Noguera, J; (...); Juan-Vidal, O
Correction. 10.1007/s12094-018-1916-2. 2018
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study
Bondarenko, I; (...); Reinmuth, N
Meeting Abstract. 2018
Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Felip, E.; (...); Ganti, A.
Meeting Abstract. 10.1016/j.annonc.2021.10.159. 2021
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
Vidal, OJJ; (...); Palanca, S
Meeting Abstract. 2019
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry).
Franco, F; (...); Provencio, M
Meeting Abstract. 2021
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
Gutierrez, L; (...); Provencio, M
Article. 10.1186/s12885-021-08713-8. 2021
PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
Spigel, DR; (...); Reck, M
Meeting Abstract. 2021
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa, Lucia; (...); Sanchez-Beato, Margarita
Article. 10.1038/s41598-020-80376-0. 2021
Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
Jantus-Lewintre, E; (...); Grp Espanol Canc Pulmon GECP
Article. 10.3389/fonc.2021.695038. 2021
Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+
Talbot, D; (...); Ong, TJ
Meeting Abstract. 10.1016/j.jtho.2018.08.649. 2018
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
Aix, SP; (...); Morgensztern, D
Article. 10.2217/fon-2019-0796. 2020
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman, Martin J.; (...); DISTINCT Study Investigators
Article. 10.1016/j.lungcan.2022.03.003. 2022
Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprenhensive Genomic Profiling in NSCLC. LungONE Study
Carpeno, JD; (...); Rojo, F
Meeting Abstract. 2019
Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with >= 50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
Perea, J.; (...); Gaudens, P. Capdevila
Meeting Abstract. 2023
RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Paz-Ares, Luis; (...); Bunn, Paul A.
Article. 10.1002/cncr.34123. 2022
RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)
Ponce, S; (...); Bunn, PA
Meeting Abstract. 10.1016/j.annonc.2020.08.1554. 2020
RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer
Paz-Ares, L; (...); Bunn, P
Meeting Abstract. 2021
RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting
Paz-Ares, L; (...); Bunn, P
Meeting Abstract. 2021
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
Spigel, DR; (...); Bunn, P
Meeting Abstract. 2020
RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
Paz-Ares, Luis G.; (...); Bunn, Paul
Meeting Abstract. 2020
RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer-Preliminary findings from part 1 dose-defining phase.
Paz-Ares, Luis G.; (...); Bunn, Paul A.
Meeting Abstract. 2019
RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
Conde, E.; (...); Lopez-Rios, F.
Meeting Abstract. 2021
RET Fusion Testing in Patients With NSCLC: The RETING Study.
Conde, Esther; (...); Lopez-Rios, Fernando
Article. 10.1016/j.jtocrr.2024.100653. 2024
RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
Hernandez, S.; (...); Conde, E.
Meeting Abstract. 2022
Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
Paz-Ares, Luis G.; (...); Garassino, Marina Chiara
Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8500. 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
Paz-Ares, Luis G.; (...); Garassino, Marina Chiara
Article. 10.1200/JCO.24.00733. 2024
Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01
Garassino, M. C.; (...); Paz-Ares, L. G.
Meeting Abstract. 2024
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.
Spigel DR; (...); Reck M
Article. 10.1016/j.annonc.2021.01.071. 2021
Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)
Carcereny Costa, E.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2022.02.062. 2022
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
Majem M; (...); Provencio M
Article. 10.1007/s12094-018-1978-1. 2019
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Garcia-Campelo, Rosario; (...); Domine, Manuel
Article. 10.1007/s12094-023-03216-3. 2023
SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).
Guma, Josep; (...); Provencio, Mariano
Article. 10.1007/s12094-023-03206-5. 2023
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.
Provencio, Mariano; (...); Cobo, Manuel
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8531. 2021
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.
Provencio, Mariano; (...); Cobo, Manuel
Article. 10.21037/tlcr-21-504. 2022
Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach.
Vera, Ruth; (...); del Alba, Aranzazu Gonzalez
Article. 10.1007/s12094-023-03112-w. 2023
Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
Suay, Guillermo; (...); Juan-Vidal, Oscar
Review. 10.3390/cancers15184433. 2023
Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)
Carcereny Costa, E.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2020.08.1547. 2020
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
Castro, RL; (...); Provencio, M
Meeting Abstract. 2019
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
Peressini M; (...); Zugazagoitia J
Article. 10.1158/1078-0432.CCR-24-0104. 2024
Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.
Mielgo-Rubio X; (...); Couñago F
Editorial Material. 10.5306/wjco.v11.i12.983. 2020
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant
Provencio-Pulla, Mariano; (...); Romero, Atocha
Meeting Abstract. 2023
Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
Blanco, R; (...); Vidal, OJJ
Meeting Abstract. 10.1016/j.annonc.2020.08.1631. 2020
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ; (...); Paz-Ares L
Article. 10.1056/NEJMoa2307980. 2023
Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/ijms23158526. 2022
The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.
Edelman, M; (...); Deng, CQ
Meeting Abstract. 2020
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gomez Rueda, Ana; (...); Garrido, Pilar
Article. 10.1007/s12094-024-03404-9. 2024
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain.
Franco, F; (...); Provencio, M
Meeting Abstract. 2021
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients
Wilhelmina Bracht, Jillian; (...); Rosell, Rafael
Meeting Abstract. 10.1158/1538-7445.AM2020-929. 2020
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
Mendez, M; (...); Provencio, M
Article. 10.1002/hon.2601. 2019
Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer
Palanca-Ballester, Cora; (...); Sandoval, Juan
Article. 10.1186/s13148-022-01334-3. 2022
Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.
Isla D; (...); Juan-Vidal O
Article. 10.1007/s12094-020-02518-0. 2021
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
Gonzalez-Rincon, J; (...); Sanchez-Beato, M
Article. 10.1371/journal.pone.0212813. 2019
Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer with untreated brain metastases.
Nadal, Ernest; (...); Bruna, Jordi
Meeting Abstract. 2022
Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy
Garcia, SV; (...); Andres, JLP
Article. 10.1016/j.yrtph.2018.10.002. 2018
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report.
Simarro J; (...); Palanca S
Article. 10.3390/diagnostics12051266. 2022
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023